Evolus to Report Third Quarter 2022 Results and Provide Business Update
10/25/2022 - 08:45 AM
NEWPORT BEACH, Calif. --(BUSINESS WIRE)--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2022 financial results and provide a business update on Tuesday, November 8, 2022 , after the U.S. financial markets close.
Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184 (U.S. ) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com .
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S. ) or (201) 612-7415 (international) and using conference number 13733400. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com .
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on LinkedIn , Twitter , Instagram or Facebook .
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source version on businesswire.com : https://www.businesswire.com/news/home/20221025005217/en/
David K. Erickson , Evolus, Inc.
david.erickson@evolus.com
Source: Evolus
EOLS Rankings
#2678 Ranked by Stock Gains
EOLS Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
US
City
Newport Beach
About EOLS
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
